受体酪氨酸激酶样孤儿受体1与肿瘤细胞信号通路关系的研究进展

其力木格; 李雪连; 纪强

doi:10.7619/jcmp.20231087

受体酪氨酸激酶样孤儿受体1与肿瘤细胞信号通路关系的研究进展

1.
阳光融和医院药学部临床药学室, 山东潍坊, 261061
2.
哈尔滨医科大学药学院药理教研室心血管药物研究教育部重点实验室, 黑龙江哈尔滨, 150081

基金项目:

国家自然科学基金面上项目 81870211

详细信息

通讯作者:
纪强, E-mail: ygrhyjk@163.com

中图分类号: R364.5;R730
计量
- 文章访问数: 158
- HTML全文浏览量: 62
- PDF下载量: 31
出版历程
- 收稿日期: 2023-04-05
- 修回日期: 2023-05-25
- 网络出版日期: 2023-09-18
- 刊出日期: 2023-09-14

Research progress on relationship between receptor tyrosine kinase-like orphan receptor 1 and signaling pathway of tumor cells

1.
Room of Clinical Pharmacy, Department of Pharmacy of Sunshine Union Hospital, Weifang, Shandong, 261061
2.
Key Laboratory of Cardiovascular Medicine Research of Ministry of Education, Teaching and Research Section of Pharmacology of College of Pharmacy of Harbin Medical University, Harbin, Heilongjiang, 150081

摘要

摘要:
受体酪氨酸激酶样孤儿受体1(ROR1)属于受体酪氨酸激酶(RTKs)大家族的一种表面跨膜蛋白, 在调控骨骼与神经的发育, 细胞迁移与细胞极性中有重要作用。ROR1在正常组织中表达低或不表达, 在肿瘤组织中高表达。研究发现ROR1能与配体螯合来调节Wnt等多种细胞信号通路, 从而在多种疾病尤其是恶性肿瘤中发挥重要的作用, 逐渐成为恶性肿瘤的治疗靶标。本文就ROR1在恶性肿瘤中与细胞信号通路相互作用及靶向ROR1肿瘤免疫治疗的研究进展进行综述, 为肿瘤临床治疗策略的制订提供参考。
- 受体酪氨酸激酶样孤儿受体1 /
- 恶性肿瘤 /
- 细胞内信号通路 /
- 肿瘤免疫治疗
Abstract:
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) belongs to the transmembrane protein family of receptor tyrosine kinases (RTKs), and plays an important role in regulating the development of bones and nerves as well as cell migration and cell polarity. ROR1 is expressed at low or no levels in normal tissues, but is highly expressed in tumor tissues. Researches have found that ROR1 can regulate various cell signaling pathways such as Wnt through chelating with ligand, thereby playing an important role in multiple diseases, especially malignant tumors, and gradually become a therapeutic target for malignant tumors. This paper reviewed the interactions between ROR1 and cell signaling pathways in malignant tumors, the researches on targeted ROR1 tumor immunotherapy in order to provide references for clinical therapeutic strategies for tumors.
- receptor tyrosine kinase-like orphan receptor 1 /
- malignant tumors /
- intracellular signaling pathway /
- tumor immunotherapy

HTML全文

参考文献(57)

[1]	MASIAKOWSKI P, CARROLL R D. A novel family of cell surface receptors with tyrosine kinase-like domain[J]. J Biol Chem, 1992, 267(36): 26181-26190. doi: 10.1016/S0021-9258(18)35733-8
[2]	GHADERI A, OKHOVAT M A, WIKANTHI L S S, et al. A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1⁺ CLL cells[J]. EJHaem, 2021, 2(3): 498-502. doi: 10.1002/jha2.232
[3]	HOJJAT-FARSANGI M, MOSHFEGH A, SCHULTZ J, et al. Targeting the receptor tyrosine kinase ROR1 by small molecules[J]. Handb Exp Pharmacol, 2021, 269: 75-99.
[4]	KIPPS T J. ROR1: an orphan becomes apparent[J]. Blood, 2022, 140(14): 1583-1591. doi: 10.1182/blood.2021014760
[5]	ZHAO Y M, ZHANG D Y, GUO Y, et al. Tyrosine kinase ROR1 as a target for anti-cancer therapies[J]. Front Oncol, 2021, 11: 680834. doi: 10.3389/fonc.2021.680834
[6]	RIM E Y, CLEVERS H, NUSSE R. The Wnt pathway: from signaling mechanisms to synthetic modulators[J]. Annu Rev Biochem, 2022, 91: 571-598. doi: 10.1146/annurev-biochem-040320-103615
[7]	NEUHAUS J, WEIMANN A, BERNDT-PAETZ M. Immunocytochemical analysis of endogenous frizzled-(co-) receptor interactions and rapid Wnt pathway activation in mammalian cells[J]. Int J Mol Sci, 2021, 22(21): 12057. doi: 10.3390/ijms222112057
[8]	MENCK K, HEINRICHS S, BADEN C, et al. The WNT/ROR pathway in cancer: from signaling to therapeutic intervention[J]. Cells, 2021, 10(1): 142. doi: 10.3390/cells10010142
[9]	MA F, ARAI S, WANG K S, et al. Autocrine canonical Wnt signaling primes noncanonical signaling through ROR1 in metastatic castration-resistant prostate cancer[J]. Cancer Res, 2022, 82(8): 1518-1533. doi: 10.1158/0008-5472.CAN-21-1807
[10]	FUKUDA T, CHEN L G, ENDO T, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a[J]. Proc Natl Acad Sci USA, 2008, 105(8): 3047-3052. doi: 10.1073/pnas.0712148105
[11]	GHADERI A, DANESHMANESH A H, MOSHFEGH A, et al. ROR1 is expressed in diffuse large B-cell lymphoma (DLBCL) and a small molecule inhibitor of ROR1(KAN0441571C) induced apoptosis of lymphoma cells[J]. Biomedicines, 2020, 8(6): 170. doi: 10.3390/biomedicines8060170
[12]	HASAN M K, GHIA E M, RASSENTI L Z, et al. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism[J]. Leukemia, 2021, 35(6): 1621-1630. doi: 10.1038/s41375-020-01055-7
[13]	HASAN M K, WIDHOPF G F 2nd, ZHANG S P, et al. Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis[J]. NPJ Breast Cancer, 2019, 5: 35. doi: 10.1038/s41523-019-0131-9
[14]	HASAN M K, YU J, CHEN L, et al. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells[J]. Leukemia, 2017, 31(12): 2615-2622. doi: 10.1038/leu.2017.133
[15]	SUTHON S, LIN J J, PERKINS R S, et al. Estrogen receptor alpha and NFATc₁ bind to a bone mineral density-associated SNP to repress WNT5B in osteoblasts[J]. Am J Hum Genet, 2022, 109(1): 97-115. doi: 10.1016/j.ajhg.2021.11.018
[16]	KATOH M. WNT/PCP signaling pathway and human cancer (review)[J]. Oncol Rep, 2005, 14(6): 1583-1588.
[17]	BAI Y, LIU C D, ZHOU J F, et al. Molecular, functional, and gene expression analysis of zebrafish Ror1 receptor[J]. Fish Physiol Biochem, 2019, 45(1): 355-363. doi: 10.1007/s10695-018-0567-0
[18]	WEISSENBÖCK M, LATHAM R, NISHITA M, et al. Genetic interactions between Ror2 and Wnt9a, Ror1 and Wnt9a and Ror2 and Ror1: Phenotypic analysis of the limb skeleton and palate in compound mutants[J]. Genes Cells, 2019, 24(4): 307-317. doi: 10.1111/gtc.12676
[19]	TEUFEL S, WOLFF L, KÖNIG U, et al. Mice lacking Wnt9a or Wnt4 are prone to develop spontaneous osteoarthritis with age and display alteration in either the trabecular or cortical bone compartment[J]. J Bone Miner Res, 2022, 37(7): 1335-1351. doi: 10.1002/jbmr.4569
[20]	KAMIZAKI K, ENDO M, MINAMI Y, et al. Role of noncanonical Wnt ligands and Ror-family receptor tyrosine kinases in the development, regeneration, and diseases of the musculoskeletal system[J]. Dev Dyn, 2021, 250(1): 27-38. doi: 10.1002/dvdy.151
[21]	TEH M T, BLAYDON D, GHALI L R, et al. Role for WNT16B in human epidermal keratinocyte proliferation and differentiation[J]. J Cell Sci, 2007, 120(Pt 2): 330-339.
[22]	KARVONEN H, PERTTILÄ R, NIININEN W, et al. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting[J]. Oncogene, 2019, 38(17): 3288-3300. doi: 10.1038/s41388-018-0670-9
[23]	AKBARZADEH M, MIHANFAR A, AKBARZADEH S, et al. Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer[J]. Life Sci, 2021, 285: 119984. doi: 10.1016/j.lfs.2021.119984
[24]	KARVONEN H, CHIRON D, NIININEN W, et al. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma[J]. Blood Adv, 2017, 1(24): 2257-2268. doi: 10.1182/bloodadvances.2017010215
[25]	FRENQUELLI M, CARIDI N, ANTONINI E, et al. The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation[J]. Leukemia, 2020, 34(1): 257-270. doi: 10.1038/s41375-019-0486-9
[26]	ZHANG Q, WANG H Y, LIU X B, et al. Cutting edge: ROR1/CD19 receptor complex promotes growth of mantle cell lymphoma cells independently of the B cell receptor-BTK signaling pathway[J]. J Immunol, 2019, 203(8): 2043-2048. doi: 10.4049/jimmunol.1801327
[27]	MAO Y, XU L, WANG J, et al. ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway[J]. Biofactors, 2019, 45(3): 416-426. doi: 10.1002/biof.1498
[28]	LONG M P, WANG H L, LUO Y B, et al. Targeting ROR1 inhibits epithelial to mesenchymal transition in human lung adenocarcinoma via mTOR signaling pathway[J]. Int J Clin Exp Pathol, 2018, 11(10): 4759-4770.
[29]	SANCHEZ-LOPEZ E, GHIA E M, ANTONUCCI L, et al. NF-κB-p62-NRF₂ survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia[J]. Cell Death Differ, 2020, 27(7): 2206-2216. doi: 10.1038/s41418-020-0496-1
[30]	ZHOU Q, ZHOU S Y, WANG H L, et al. Stable silencing of ROR1 regulates cell cycle, apoptosis, and autophagy in a lung adenocarcinoma cell line[J]. Int J Clin Exp Pathol, 2020, 13(5): 1108-1120.
[31]	WANG H L, LIU Y C, LONG M P, et al. Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines[J]. Oncol Lett, 2019, 18(3): 2977-2984.
[32]	LIU Y C, YANG H, CHEN T X, et al. Silencing of receptor tyrosine kinase ROR1 inhibits tumor-cell proliferation via PI3K/AKT/mTOR signaling pathway in lung adenocarcinoma[J]. PLoS One, 2015, 10(5): e0127092. doi: 10.1371/journal.pone.0127092
[33]	YAMAGUCHI T, YANAGISAWA K, SUGIYAMA R, et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma[J]. Cancer Cell, 2012, 21(3): 348-361. doi: 10.1016/j.ccr.2012.02.008
[34]	FULTANG N, ILLENDULA A, LIN J H, et al. ROR1 regulates chemoresistance in Breast Cancer via modulation of drug efflux pump ABCB1[J]. Sci Rep, 2020, 10(1): 1821. doi: 10.1038/s41598-020-58864-0
[35]	FULTANG N, ILLENDULA A, CHEN B, et al. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3 activity[J]. PLoS One, 2019, 14(5): e0217789. doi: 10.1371/journal.pone.0217789
[36]	DAI B, SHEN Y C, YAN T, et al. Wnt5a/ROR1 activates DAAM1 and promotes the migration in osteosarcoma cells[J]. Oncol Rep, 2020, 43(2): 601-608.
[37]	CHEN J, YUE C Y, XU J E, et al. Downregulation of receptor tyrosine kinase-like orphan receptor 1 in preeclampsia placenta inhibits human trophoblast cell proliferation, migration, and invasion by PI3K/AKT/mTOR pathway accommodation[J]. Placenta, 2019, 82: 17-24. doi: 10.1016/j.placenta.2019.05.002
[38]	ZENG Z X, GU S S, OUARDAOUI N, et al. Hippo signaling pathway regulates cancer cell-intrinsic MHC-Ⅱ expression[J]. Cancer Immunol Res, 2022, 10(12): 1559-1569. doi: 10.1158/2326-6066.CIR-22-0227
[39]	XIAO Y, DONG J X. The hippo signaling pathway in cancer: a cell cycle perspective[J]. Cancers, 2021, 13(24): 6214. doi: 10.3390/cancers13246214
[40]	LI C L, WANG S Y, XING Z, et al. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis[J]. Nat Cell Biol, 2017, 19(2): 106-119. doi: 10.1038/ncb3464
[41]	ISLAM S S, UDDIN M, NOMAN A S M, et al. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1[J]. EBioMedicine, 2019, 43: 211-224. doi: 10.1016/j.ebiom.2019.04.061
[42]	KARVONEN H, BARKER H, KALEVA L, et al. Molecular mechanisms associated with ROR1-mediated drug resistance: crosstalk with hippo-YAP/TAZ and BMI-1 pathways[J]. Cells, 2019, 8(8): 812. doi: 10.3390/cells8080812
[43]	NADANAKA S, TAMURA J I, KITAGAWA H. Chondroitin sulfates control invasiveness of the basal-like breast cancer cell line MDA-MB-231 through ROR1[J]. Front Oncol, 2022, 12: 914838. doi: 10.3389/fonc.2022.914838
[44]	KATOH M, KATOH M. Molecular genetics and targeted therapy of WNT-related human diseases (Review)[J]. Int J Mol Med, 2017, 40(3): 587-606.
[45]	ZHANG J, ZHANG W, ZHANG Q L. Ectopic expression of ROR1 prevents cochlear hair cell loss in guinea pigs with noise-induced hearing loss[J]. J Cell Mol Med, 2020, 24(16): 9101-9113. doi: 10.1111/jcmm.15545
[46]	IROEGBU J D, IJOMONE O K, FEMI-AKINLOSOTU O M, et al. ERK/MAPK signalling in the developing brain: Perturbations and consequences[J]. Neurosci Biobehav Rev, 2021, 131: 792-805. doi: 10.1016/j.neubiorev.2021.10.009
[47]	BUTTURINI E, CARCERERI DE PRATI A, MARIOTTO S. Redox regulation of STAT1 and STAT3 signaling[J]. Int J Mol Sci, 2020, 21(19): 7034. doi: 10.3390/ijms21197034
[48]	IKEDA T, NISHITA M, HOSHI K, et al. Mesenchymal stem cell-derived CXCL16 promotes progression of gastric cancer cells by STAT3-mediated expression of Ror1[J]. Cancer Sci, 2020, 111(4): 1254-1265. doi: 10.1111/cas.14339
[49]	LI P, HARRIS D, LIU Z M, et al. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells[J]. PLoS One, 2010, 5(7): e11859. doi: 10.1371/journal.pone.0011859
[50]	ROZOVSKI U, HARRIS D M, LI P, et al. STAT3-induced Wnt5a provides chronic lymphocytic leukemia cells with survival advantage[J]. J Immunol, 2019, 203(11): 3078-3085. doi: 10.4049/jimmunol.1900389
[51]	DANESHMANESH A H, HOJJAT-FARSANGI M, KHAN A S, et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells[J]. Leukemia, 2012, 26(6): 1348-1355. doi: 10.1038/leu.2011.362
[52]	BAYAT A A, SADEGHI N, FATEMI R, et al. Monoclonal antibody against ROR1 induces apoptosis in human bladder carcinoma cells[J]. Avicenna J Med Biotechnol, 2020, 12(3): 165-171.
[53]	LIU D L, KAUFMANN G F, BREITMEYER J B, et al. The anti-ROR1 monoclonal antibody zilovertamab inhibits the proliferation of ovarian and endometrial cancer cells[J]. Pharmaceutics, 2022, 14(4): 837. doi: 10.3390/pharmaceutics14040837
[54]	CHOI M Y, WIDHOPF G F 2nd, GHIA E M, et al. Phase Ⅰ trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia[J]. Cell Stem Cell, 2018, 22(6): 951-959. e3. doi: 10.1016/j.stem.2018.05.018
[55]	AGHEBATI-MALEKI L, YOUNESI V, BARADARAN B, et al. Antiproliferative and apoptotic effects of novel anti-ROR1 single-chain antibodies in hematological malignancies[J]. SLAS Discov, 2017, 22(4): 408-417. doi: 10.1177/2472555216689659
[56]	YIN Z N, GAO M Y, CHU S S, et al. Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells[J]. Oncotarget, 2017, 8(55): 94210-94222. doi: 10.18632/oncotarget.21618
[57]	VAISITTI T, ARRUGA F, VITALE N, et al. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models[J]. Blood, 2021, 137(24): 3365-3377. doi: 10.1182/blood.2020008404

施引文献(6)

期刊类型引用(6)

1.	叶雅芳. 基于Watson关怀理论的安宁疗护干预在终末期胃肠道肿瘤患者中的应用效果研究. 黑龙江医学. 2023(23): 2918-2920+2924 . 百度学术
2.	周艳. 基于M-health中青年胃肠道肿瘤术后患者自我管理支持模块的构建与应用. 当代护士(上旬刊). 2022(01): 82-86 . 百度学术
3.	陈居杲. 姑息治疗方案在高龄晚期胃肠道肿瘤患者中的疗效分析. 中国现代药物应用. 2021(06): 176-178 . 百度学术
4.	黎少红. 营养护理干预模式对晚期胃肠道肿瘤化疗患者的效果. 医学食疗与健康. 2020(10): 16-17 . 百度学术
5.	杨春柳，张颖元，石壬伟. 盐酸特比萘芬乳膏联合伊曲康唑胶囊治疗甲真菌感染的疗效观察. 当代医学. 2020(28): 108-110 . 百度学术
6.	赵冬芳. 姑息护理干预对晚期胃肠道肿瘤患者的影响. 中国实用医药. 2020(33): 175-177 . 百度学术